16 March 2021
09:00 am PT | 12:00 pm ET | 16:00 GMT | 17:00 CET
Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to increase. If the treatment is CAR-T cells, adoptive T cell therapy or checkpoint inhibitors, the mechanism of action includes T cell lysis of tumor cells.
Using fluorescent labels of cytotoxicity, Incucyte® Live-Cell Analysis offers remote monitoring of tumor cell lysis. This webinar presents data using tumor antigen specific T cells from Cellero and commonly available tumor cell lines, to demonstrate specific lysis of tumor cells.
Key webinar discussion topics include:
Information on crucial technical factors
Comparison of Annexin V and Caspase 3/7 for readout and analysis options
The use of adherent vs suspension cells as targets
Controls, and establishing specificity of killing
The importance of plating density of target cells
Live questions and answers
Dr. Anne Lodge
Chief Science & Innovation Officer
Anne Lodge received her Ph.D. in Cell and Molecular Biology from the University of Vermont. Her thesis work examined the activation of CD4+ and CD8+ T cells by vascular endothelium and revealed the importance of endothelial cells in triggering organ rejection.
After completing her graduate work, Dr. Lodge received a postdoctoral fellowship from the Multiple Sclerosis Society. The fellowship supported her work at Vanderbilt University in the laboratory of Dr. Subramaniam Sriram. She studied T cells from patients with MS to determine their role in the disease process.
Dr. Lodge then accepted a position with Northwest Biotherapeutics, Inc. in Seattle. She had a number of different roles at the company and contributed to the Investigational New Drug filings for the company’s dendritic cell vaccine. Her expertise in cell-based therapeutics and broad background in immunology led to her founding Astarte Biologics in 2004 to provide immune cell products for research.